[go: up one dir, main page]

WO2009008487A1 - 被覆製剤 - Google Patents

被覆製剤 Download PDF

Info

Publication number
WO2009008487A1
WO2009008487A1 PCT/JP2008/062523 JP2008062523W WO2009008487A1 WO 2009008487 A1 WO2009008487 A1 WO 2009008487A1 JP 2008062523 W JP2008062523 W JP 2008062523W WO 2009008487 A1 WO2009008487 A1 WO 2009008487A1
Authority
WO
WIPO (PCT)
Prior art keywords
pioglytazone
preparation
salt
individual
coating layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/062523
Other languages
English (en)
French (fr)
Inventor
Hiroto Bando
Yoshihiro Omachi
Kenichiro Kiyoshima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to JP2009522677A priority Critical patent/JP5350240B2/ja
Priority to EP08791071.7A priority patent/EP2172200B1/en
Priority to US12/452,587 priority patent/US9427434B2/en
Publication of WO2009008487A1 publication Critical patent/WO2009008487A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

　本発明は、ピオグリタゾン又はその塩を活性成分とする製剤であって、ピオグリタゾンのバイオアベイラビリティーが高く、かつ薬物血中濃度の個体間バラツキが少ない製剤を提供する。また、本発明は、保存時の着色変化が抑制された製剤を提供する。該製剤は、２０°Cにおける水に対する溶解度が１０ｍｇ／ｍＬ以上であり、かつ２５°Cにおける第一酸解離定数Ｋａ１の負の常用対数ｐＫａ１が５以下である、製薬上許容される有機酸を含む核と、ピオグリタゾン又はその塩を含む被覆層とを含む。該被覆層はマンニトール又はトレハロースをさらに含み得る。
PCT/JP2008/062523 2007-07-12 2008-07-10 被覆製剤 Ceased WO2009008487A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009522677A JP5350240B2 (ja) 2007-07-12 2008-07-10 被覆製剤
EP08791071.7A EP2172200B1 (en) 2007-07-12 2008-07-10 Coated preparation
US12/452,587 US9427434B2 (en) 2007-07-12 2008-07-10 Coated preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007183749 2007-07-12
JP2007-183749 2007-07-12

Publications (1)

Publication Number Publication Date
WO2009008487A1 true WO2009008487A1 (ja) 2009-01-15

Family

ID=40228658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/062523 Ceased WO2009008487A1 (ja) 2007-07-12 2008-07-10 被覆製剤

Country Status (6)

Country Link
US (1) US9427434B2 (ja)
EP (1) EP2172200B1 (ja)
JP (1) JP5350240B2 (ja)
AR (1) AR067491A1 (ja)
TW (1) TW200914006A (ja)
WO (1) WO2009008487A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503876A (ja) * 2009-09-02 2013-02-04 ジオファーム オンコロジー インク インジブリンに関する薬学的組成物
JP2013506648A (ja) * 2009-09-30 2013-02-28 メルク シャープ エンド ドーム リミテッド ｃ−ＭＥＴキナーゼ阻害剤の製剤
JP2013521332A (ja) * 2010-03-05 2013-06-10 ユニヴァーシティー オヴ ストラスクライド パルス状薬剤放出
JP2014530802A (ja) * 2011-10-21 2014-11-20 武田薬品工業株式会社 徐放性製剤

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
MX2011001671A (es) 2008-08-12 2011-06-17 Zinfandel Pharmaceuticals Inc Metodo de identificacion de factores de riesgo de la enfermedad.
MX339844B (es) 2011-01-10 2016-06-13 Takeda Pharmaceuticals Co Metodos y productos de farmaco para tratar enfermedad de alzheimer.
WO2013055609A1 (en) * 2011-10-12 2013-04-18 Merck Sharp & Dohme Corp. Pharmaceutical compositions that inhibit disproportionation
WO2013106526A1 (en) * 2012-01-10 2013-07-18 Teva Pharmaceutical Industries Ltd. Saxagliptin parmaceutical formulations
TR201902206T4 (tr) * 2013-06-17 2019-03-21 Nippon Soda Co Hidroksialkil selüloz içeren kaplama ajanı.

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006130A1 (fr) * 1986-04-16 1987-10-22 Laboratoires Delagrange Comprimes a matrice
WO1993009781A1 (fr) * 1991-11-14 1993-05-27 Ss Pharmaceutical Co., Ltd. Comprime de trapidile a liberation prolongee
JPH05262767A (ja) * 1992-03-19 1993-10-12 Takeda Chem Ind Ltd 持続性製剤
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
WO1998044921A1 (en) 1997-04-04 1998-10-15 Merck & Co., Inc. Somatostatin agonists
WO1998045285A1 (en) 1997-04-04 1998-10-15 Merck & Co., Inc. Somatostatin agonists
WO1999022735A1 (en) 1997-10-30 1999-05-14 Merck & Co., Inc. Somatostatin agonists
WO2001014372A2 (en) 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent
WO2001025228A1 (en) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Amine derivatives
WO2001082925A1 (en) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonists
WO2001087834A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
WO2003042204A1 (en) 2001-10-19 2003-05-22 Takeda Chemical Industries, Ltd. Amine derivative
WO2003055525A1 (fr) * 2001-12-25 2003-07-10 Takeda Chemical Industries, Ltd. Preparations contenant un acide
WO2003074032A1 (de) * 2002-03-07 2003-09-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende darreichungsform für schwerlösliche basische wirkstoffe
WO2004006921A1 (ja) * 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited 被覆製剤の製造法
WO2004067001A1 (ja) * 2003-01-29 2004-08-12 Takeda Pharmaceutical Company Limited 被覆製剤の製造法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832625B2 (ja) * 1987-01-29 1996-03-29 武田薬品工業株式会社 有核顆粒およびその製造法
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US20010056177A1 (en) * 1997-12-20 2001-12-27 Becker Nathaniel T. Matrix granule
JP4284017B2 (ja) * 2000-10-06 2009-06-24 武田薬品工業株式会社 固形製剤
WO2002030400A1 (fr) * 2000-10-06 2002-04-18 Takeda Chemical Industries, Ltd. Preparations solides
CA2454778A1 (en) * 2001-07-06 2003-01-16 Computer Associates Think, Inc. System and method for managing object based clusters
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20050074494A1 (en) * 2003-10-06 2005-04-07 Xiu-Xiu Cheng Itraconazole immediate release formulation
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
US8632808B2 (en) * 2006-04-27 2014-01-21 Takeda Pharmaceutical Company Limited Taste-masking solid preparation of pioglitazone

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006130A1 (fr) * 1986-04-16 1987-10-22 Laboratoires Delagrange Comprimes a matrice
WO1993009781A1 (fr) * 1991-11-14 1993-05-27 Ss Pharmaceutical Co., Ltd. Comprime de trapidile a liberation prolongee
JPH05262767A (ja) * 1992-03-19 1993-10-12 Takeda Chem Ind Ltd 持続性製剤
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
WO1998044921A1 (en) 1997-04-04 1998-10-15 Merck & Co., Inc. Somatostatin agonists
WO1998045285A1 (en) 1997-04-04 1998-10-15 Merck & Co., Inc. Somatostatin agonists
WO1999022735A1 (en) 1997-10-30 1999-05-14 Merck & Co., Inc. Somatostatin agonists
WO2001014372A2 (en) 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent
WO2001025228A1 (en) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Amine derivatives
WO2001082925A1 (en) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonists
WO2001087834A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
WO2003042204A1 (en) 2001-10-19 2003-05-22 Takeda Chemical Industries, Ltd. Amine derivative
WO2003055525A1 (fr) * 2001-12-25 2003-07-10 Takeda Chemical Industries, Ltd. Preparations contenant un acide
WO2003074032A1 (de) * 2002-03-07 2003-09-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende darreichungsform für schwerlösliche basische wirkstoffe
JP2005526738A (ja) 2002-03-07 2005-09-08 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 低溶解度の薬物を経口投与するための投与剤形
WO2004006921A1 (ja) * 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited 被覆製剤の製造法
WO2004067001A1 (ja) * 2003-01-29 2004-08-12 Takeda Pharmaceutical Company Limited 被覆製剤の製造法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2172200A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503876A (ja) * 2009-09-02 2013-02-04 ジオファーム オンコロジー インク インジブリンに関する薬学的組成物
JP2013506648A (ja) * 2009-09-30 2013-02-28 メルク シャープ エンド ドーム リミテッド ｃ−ＭＥＴキナーゼ阻害剤の製剤
JP2013521332A (ja) * 2010-03-05 2013-06-10 ユニヴァーシティー オヴ ストラスクライド パルス状薬剤放出
JP2016040309A (ja) * 2010-03-05 2016-03-24 ユニヴァーシティー オヴ ストラスクライド パルス状薬剤放出
JP2014530802A (ja) * 2011-10-21 2014-11-20 武田薬品工業株式会社 徐放性製剤

Also Published As

Publication number Publication date
EP2172200A4 (en) 2010-07-28
US9427434B2 (en) 2016-08-30
EP2172200B1 (en) 2015-09-16
EP2172200A1 (en) 2010-04-07
JP5350240B2 (ja) 2013-11-27
US20100166853A1 (en) 2010-07-01
AR067491A1 (es) 2009-10-14
JPWO2009008487A1 (ja) 2010-09-09
TW200914006A (en) 2009-04-01

Similar Documents

Publication Publication Date Title
WO2009008487A1 (ja) 被覆製剤
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
AR070033A1 (es) Composiciones inyectables, sus procesos y usos
WO2009007751A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2009007748A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2009007749A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
CN101237838A (zh) 治疗免疫炎性疾病的联合疗法
WO2007087431A3 (en) Sublingual fentanyl spray
WO2009017837A3 (en) Sublingual fentanyl spray
WO2008062440A3 (en) Programmable buoyant delivery technology
WO2010117873A3 (en) Progesterone solutions for increased bioavailability
WO2011066980A3 (en) Oral dosage forms with reduced potential for drug abuse
WO2008044236A3 (en) Improved release of statins in the intestine
WO2008143240A1 (ja) 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
RU2015102772A (ru) Бензодиазелипы для мелкоклеточного рака легкого
WO2011076209A3 (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
NZ591204A (en) Pharmaceutical compositions and methods for stabilizing the same
WO2004098594A3 (en) Dosage form containing pantoprazole as active ingredient
TW200745136A (en) 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
WO2008061671A3 (en) Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
WO2009024590A3 (en) Antifungal composition
EP1152002A4 (en) PYRROL DERIVATIVES AND CELL DEATH INHIBITORS
WO2004098577A3 (en) Dosage form containing (s)-pantoprazole as active ingredient
RU2018114922A (ru) Лечение очаговой алопеции
EP2730271B1 (en) Aqeuous compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08791071

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009522677

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12452587

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2008791071

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE